A role of late Epstein-Barr virus infection in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 109, Issue 4, 2004, Pages 270-275

  Haahr, S ^a   Plesner, A M ^b   Vestergaard, B F ^b   Hollsberg P ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Case control studies; Epstein Barr virus; Late infection; Multiple sclerosis

Indexed keywords

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; INFECTIOUS MONONUCLEOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREVALENCE; PUBERTY; RISK FACTOR; SCHOOL CHILD; SEROCONVERSION; VIRUS INFECTION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CHILD; DENMARK; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MULTIPLE SCLEROSIS; SEROLOGIC TESTS; VIRUS ACTIVATION;

EID: 1642565888     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-0404.2003.00221.x     Document Type: Article

References (39)

1. MARTIN R, MCFARLAND HF, MCFARLIN DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-87.
2. EBERS GC, BULMAN DE, SADOVNICK AD et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986;315:1638-42.
3. KURTZKE JF. Epidemiological evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382-427.
4. MARTYN CN. The epidemiology of multiple sclerosis. In: MATTHEWS WB, ed. McAlpin's multiple sclerosis. Edinburg, London, Melbourne and New York: Churchill Livingston, 1991;3-40.
5. GALE CR, MARTYN CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995;47:425-48.
6. WAKSMAN BH. More genes versus environment. Nature 1995;377:105-6.
7. ALTER M, ZHEN-XIN Z, DAVANPOUR Z et al. Multiple sclerosis and childhood infections. Neurology 1986;36:1386-98.
8. HAAHR S, KOCH-HENRIKSEN N, MØLLER-LARSEN A et al. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mul Scler 1995;1:73-77.
9. WARNER HB, CARP RI. Multiple sclerosis etology - an Epstein-Barr virus hypothesis. Med Hypotheses 1988;25:93-7.
10. RIISE T, GRONNING M, KLAUBER MR, BARRETT-CONNOR E, NYLAND H, ALBREKTSEN G. Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway. Am J Epidemiol 1991;133:932-39.
11. HAAHR S, HÖLLSBERG P. The ability of candidate viruses to explain the epidemiological findings in multiple sclerosis. In: HOMMES OR, CLANET M, WEKERLE H, eds. Genes and viruses in multiple sclerosis. Amsterdam: Elsevier Science B.V. 2001;163-84.
12. HOSSAIN A. Seroepidemiology of Epstein-Barr virus infections in a developing country. J Trop Pediatr 1987;33:257-60.
13. VENKITARAMAN AR, LENOIR GM, JOHN TJ. The seroepidemiology of infection due to Epstein-Barr virus in southern India. J Med Virol 1985;1:11-6.
14. COMI G. A multicenter study of the incidence of multiple sclerosis in Italy: design of the study. Ital J Neurol Sci 1987;6:S21-5.
15. LEOGRANDE G, JIRILLO E. Studies on the epidemiology of child infections in the Bari area (South Italy) VII. Epidemiology of Epstein-Barr virus infections. Eur J Epidemiol 1993;9:368-73.
16. EVANS AS, NIEDERMAN JC. Epstein-Barr virus. In: EVANS AS, ed. Viral infections of humans. Epidemiology and control, 3rd edn. New York and London: Plenum Book Company, 1989;263-95.
17. PEREIRA MS, BLAKE JM, MACRAE AD. EB virus antibody at different ages. BMJ 1969;4:526-7.
18. KESSEL I, POLLOCK TM, EDWARDS JMB et al. Epstein-Barr virus infection in children entering a pediatric unit. J Infect 1980;2:269-74.
19. PLESNER AM. Measles, mumps and rubella (MMR) vaccination programme. Ph.D. thesis, University of Copenhagen. 1998.
20. FARBER I, WUTZLER P WOHLRABE P, WOLF H, HINDERER W, SONNEBORN HH. Serological diagnosis of infectious mononucleosis using three anti-Epstein-Barr virus recombinant ELISAs. J Virol Methods 1993;42:301-7.
21. SUMAYA CV, MYERS LW, ELLISON GW ENCH Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985; 17:371-7.
22. MUNCH M, RIISOM K, CHRISTENSEN T, et al. The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients? Acta Neurol Scand 1998;97:171-4.
23. OPERSKALSKI EA, VISSCHER BR, MALMGREN RM, DETELS R. A case-control study of multiple sclerosis. Neurology 1989;39:825-39.
24. MARTYN CN, CRUDDAS M, COMPSTON DAS. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:167-8.
25. MARRIE RA, WOLFSON C, STURKENBOOM MCJM et al. Multiple sclerosis and antecedent infections. A case-control study. Neurology 2000;54:2307-10.
26. HERNÁN MA, ZHANG SM, LIPWORTH L et al. Multiple sclerosis and age of infection with commen viruses. Epidemiology 2001;12:301-6.
27. SOUBERBIELLE BE, MARTIN-MONDIERE C, O'BRIEN ME et al. A case-control epidemiological study of MS in the Paris area with particular reference to past history and profession. Acta Neurol Scand 1990;82:303-10.
28. GRØNNING M, RIISE T, KVÅLE G et al. Infections in childhood and adolescence in multiple sclerosis. Neuroepidemiology 1993;12:61-9.
29. BACHMANN S, KESSELRING J. Multiple sclerosis and infectious in childhood diseases. Neuroepidemiology 1998;17:154-60.
30. GLICKMANN G, PETERSEN I, MORDHORST C. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children. Danish Med Bull 1988;35:185-187.
31. EDMUNDS WJ, GAY NJ, KRETZSCHMAR M et al. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modeling studies. Epidemiol Infect 2000;125:535-650.
32. PANITCH HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36:S25-8.
33. WANDINGER K-P, JABS W, SIEKHAUS A et al. Association between clinical disease activity and Epstein-Barr virus rectivations in MS. Neurology 2000;55:178-184.
34. MARRIE RA, WOLFSON C. Multiple sclerosis and varicella zoster virus infection: a review. Epidemiol Infect 2001;127:315-25.
35. Ross RT, CHEANG M, LANDRY G et al. Herpes zoster and multiple sclerosis. Can J Neurol Sci 1999;26:29-32.
36. BECH E, LYCKE J, GADEBERG P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002;58:31-6.
37. BRAY PF, CULP KW, MCFARLIN DE et al. Demyelinating disease after neurologically complicated primary Epstein-Barr virus infection. Neurology 1992;42:278-82.
38. WUCHERPFENNIG KW, STROMINGER JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
39. LANG HLE, JACOBSEN H, IKEMIZU S et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002;10:940-3.